Composition for preventing the occurrence of cardiovascular event in multiple risk patient
AssigneeMochida Pharmaceutical Co., Ltd.
InventorsMitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
Life of this patent
Estimating the term…
Abstract
Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
Claims38
A method of reducing occurrence of a cardiovascular event in a hypercholesterolemia patient comprising,
- identifying a patient having triglyceride (TG) of at least 150 mg/dL and HDL-Cholesterol (HDL-C) of less than 40 mg/dL in a blood sample taken from the patient, wherein the patient has not previously had a cardiovascular event, and administering ethyl icosapentate and/or icosapentaenoic acid in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, wherein the patient optionally also suffers from at least one risk factor selected from the group consisting of:
- (1) obesity,
- (2) hypertension or prehypertension, and
- (3) diabetes, prediabetes, or abnormal glucose tolerance.
A method of reducing occurrence of a cardiovascular event in a hypercholesterolemia patient comprising,
- identifying the patient has not previously had a cardiovascular event, and administering ethyl icosapentate and/or icosapentaenoic acid in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, wherein the patient also suffers from the following (1)-(4):
- (1) obesity,
- (2) hypertension or prehypertension,
- (3) diabetes, prediabetes, or abnormal glucose tolerance, and
- (4) hypertriglyceridemia and/or low HDL cholesterolemia.
A method of reducing occurrence of a cardiovascular event in a male hypercholesterolemia patient comprising,
- identifying the male patient has not previously had a cardiovascular event, and administering ethyl icosapentate and/or icosapentaenoic acid in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, wherein the patient also suffers from at least two risk factors selected from the group consisting of:
- (1) obesity,
- (2) hypertension or prehypertension,
- (3) diabetes, prediabetes, or abnormal glucose tolerance, and
- (4) hypertriglyceridemia and/or low HDL cholesterolemia.
Dependencies are inferred from the claim text.